Skip to main content
Support Quality Journalism.
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just
$1.99
per week
for first 24 weeks
Enjoy unlimited digital access
START TODAY
Get full access to globeandmail.com
Just $1.99 per week
for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //
The Globe and Mail
Member Benefits
Subscribe
Subscribe
Register
Log in
My account
Following
Bookmarks
Reading history
Newsletters
Subscriptions
Settings
Help
My account
Following
Bookmarks
Reading history
Newsletters
Subscriptions
Settings
Help
AdChoices
Canada
World
Business
Investing
Opinion
Politics
Sports
Life
Arts
Drive
Real Estate
Watchlist
Search
Search
Quick links
Horoscopes
Puzzles
Member Benefits
Newsletters
Globe Shop
Investigations
Death Notices (Legacy.com)
Reader services
Subscribe
Following
Subscriptions
Settings
Customer Help
Contact us
Log in
Log out
Purdue University
Follow
Latest
politics
McKinsey is open to settlement regarding opioid work in the U.S. and Canada
January 29
Updated
canada
At the root of the opioid crisis is our belief that Big Pharma can cure pain. Can we kick that habit?
January 9
Updated
u.s. business
Sacklers cited fear of OxyContin lawsuits before transferring US$10-billion from Purdue Pharma, documents show
December 21
Updated
politics
Canadian envoy silent on his knowledge of McKinsey role in Purdue opioid sales
December 14
Updated
international business
OxyContin maker Purdue Pharma pleads guilty in criminal case
November 24
Updated
canada
Canada’s provinces have filed opioid-related claims totalling $67.4-billion in U.S. court
November 12
Updated
More Stories Below Advertisement
inside the market
Fertilizer stocks are up on good news. Here’s what they need now
October 19
Updated
u.s. business
U.S. pursues nearly $13-billion of claims in Purdue Pharma opioid probes, sources say
August 5
Updated
international business
U.S. pursues nearly $13-billion of penalties in Purdue Pharma opioid probes
August 4
Updated
u.s. business
Owners of OxyContin maker Purdue Pharma were paid more after company’s big fine for misleading marketing
December 16, 2019
Updated
canada
Purdue Pharma asks court to halt all litigation against it in Canada amid U.S. lawsuits
November 28, 2019
Updated
canada
B.C. alleges 20 years of deception in opioid lawsuit
August 29, 2018
Updated
To view this site properly, enable cookies in your browser. Read our
privacy policy
to learn more.
How to enable cookies